Incyte Corporation

Incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. Our vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs. We have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. The Incyte corporate headquarters is located in Wilmington, Delaware, and more than 625 employees comprise our experienced management, discovery, clinical development and commercial teams. Our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference by improving the lives of patients and building sustainable value for our shareholders.
Company Growth (employees)
Wilmington, US
Size (employees)
980 (est)+42%
Incyte Corporation was founded in 1991 and is headquartered in Wilmington, US

Incyte Corporation Office Locations

Incyte Corporation has offices in Wilmington, Genève, Geneva, Lausanne and in 6 other locations
Wilmington, US (HQ)
1801 Augustine Rd
Genève, CH
1 Rue du Pré-de-la-Bichette

Incyte Corporation Metrics

Incyte Corporation Financial Metrics

Revenue (2016)

$1.1 b

Revenue growth (2015-16), %


Net income (2016)

$104.2 m

Market capitalization (21-Mar-2017)

$27.8 b

Closing share price (21-Mar-2017)


Cash (31-Dec-2016)

$652.3 m
Incyte Corporation's current market capitalization is $27.8 b.
Incyte Corporation's revenue was reported to be $1.1 b in FY, 2016 which is a 46.7% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016


$354.9 m$511.5 m$753.8 m$1.1 b

Revenue growth, %


Operating expense total

$371 m$516.3 m$703.1 m$960.7 m


($16.1 m)($4.8 m)$50.7 m$145 m

EBIT margin, %


Interest expense

$38.7 m$46.8 m$45.6 m$38.7 m

Interest income

$1.3 m$3.4 m$7.1 m$4.4 m

Pre tax profit

($82.8 m)($48.5 m)

Income tax expense

$299 k($66 k)$1 m$3.2 m

Net Income

($83.1 m)($48.5 m)$6.5 m$104.2 m
FY, 2013FY, 2014FY, 2015FY, 2016


$471.4 m$452.3 m$521.4 m$652.3 m

Accounts Receivable

$35.4 m$57.9 m$114.5 m$148.8 m


$9.6 m$20.5 m$17.8 m$32.8 m

Current Assets

$555.8 m$699.2 m$842.4 m$994.2 m


$26.8 m$81.8 m$86 m$167.7 m


$155.6 m

Total Assets

$629.6 m$830.1 m$1 b$1.6 b

Accounts Payable

$19.1 m$24.5 m$30.1 m$75.6 m

Current Liabilities

$108 m$221.5 m$168 m$273.5 m

Additional Paid-in Capital

$1.5 b$1.7 b$2 b$2.1 b

Retained Earnings

($1.7 b)($1.8 b)($1.8 b)($1.7 b)

Total Equity

($193.1 m)($81.6 m)$171.2 m$419.5 m

Financial Leverage

-3.3 x-10.2 x5.9 x3.9 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($83.1 m)($48.5 m)$6.5 m$104.2 m

Depreciation and Amortization

$58.4 m

Accounts Receivable

$35.6 m($23 m)$114 m($24 m)


($6.6 m)($4.1 m)$17.8 m$4 m

Accounts Payable

$5.1 m$5.4 m$30.1 m$43.8 m

Cash From Operating Activities

$9.2 m$26.3 m$304.8 m

Capital Expenditures

($4.3 m)($27.9 m)($120.3 m)

Cash From Investing Activities

($37.4 m)($138.4 m)($232.5 m)

Interest Paid

$15.6 m$10.5 m$7.2 m

Income Taxes Paid

$927 k

Free Cash Flow

$13.4 m$54.1 m$425 m

Incyte Corporation Market Value History

Incyte Corporation Job Categories

Incyte Corporation Median Salaries

Source: 40 public H-1B filings from Incyte Corporation

Incyte Corporation Online Presence

Incyte Corporation News

Incyte Corporation Company Life

You may also be interested in